FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W137671273> ?p ?o ?g. }

• W137671273 abstract "Abstract Background Mantle cell lymphoma (MCL) is an aggressive subtype of Non-Hodgkin Lymphoma associated with poor prognosis. Constitutive activation of B-cell receptor (BCR) signaling plays an essential role for the survival and proliferation of malignant B-cells. Targeting Bruton’s tyrosine kinase (BTK), a component of BCR signaling pathway, with ibrutinib is a promising strategy. As a single agent, complete and partial response rates of 21% and 47%, respectively, were observed in a phase 2 study for relapsed or refractory MCL. Simultaneous inhibition of multiple biologic pathways has the potential to result in a synergism. We combined ibrutinib with ABT-199, a BH3 mimetic that selectively targets the BCL-2 pathway, and tested their in vitroefficacy against MCL. Experimental design A novel MCL cell line, CCMCL1, and four other MCL cell lines (Jeko-1, Mino, JVM2, Rec-1) were used for flow cytometry-based apoptosis and cell cycle analyses to evaluate the combinational effect of ibrutinib with ABT-199 (ChemieTek. Indianpolis. IN). The interaction between drugs was examined with Calcusyn software and combination index values served to determine the combined effect as synergistic (<1), additive (=1), or antagonistic (>1). Immunoblotting was performed to investigate signaling pathways of MCL cells exposed to these agents. Results CCMCL1 was derived from primary leukemic MCL cells. Cells were initially directly injected via tail vein into an NSG mouse. Engrafted cells were then isolated at 10 weeks from spleen and placed into routine cell culture. Immunophenotyping showed CCMCL1 cells have similar characteristics as the primary patient MCL cells, which expressed CD5, CD19, CD20, FMC7 and monotypic kappa light chain. Immunohistochemical staining of engrafted mouse spleen tissue showed expression of cyclin D1 and SOX11. The karyotype is highly complex with an IGH@/CCND1 fusion by metaphase FISH. In addition to spleen, MCL cell infiltration was observed in mouse liver, bone marrow, blood, brain, lung, kidney and intestine. In vitro cultured CCMCL1 cells underwent apoptosis upon expose to ibrutinib and ABT-199 as single agents. Combination of these two drugs resulted in synergistic induction of apoptosis (Table 1). Synergism was also observed with Jeko-1, Mino, JVM-2 and Rec-1 cells. Immunoblotting showed CCMCL1 cells have constitutive expression of cyclin D1, SOX11, PAX5 and MCL1. Ibrutinib as a single agent induced a rapid down-regulation of SOX11 and MCL1, while combination of ibrutinib with ABT-199 further enhanced down regulation of SOX11, followed by down-regulation of PAX5 at a later time point. We are currently testing the in vivo efficacy of combining these two drugs in a CCMCL1 NSG mouse model. Conclusion Our CCMCL1/NSG mouse model is a new model for pre-clinical assessment of MCL treatment approaches. Combination of ibrutinib with ABT-199 has synergistic effect of apoptotic induction in CCMCL1 as well as four other MCL cell lines tested. Ibrutinib or ibruitnib/ABT-199 combination induced apoptosis of MCL is associated with down-regulation of SOX11 and PAX5. Simultaneous down regulation of MCL1 via ibrutinib and targeting of BCL2 may contribute to the in vitrosynergism observed. These data support further investigation of this novel therapeutic strategy. Disclosures: No relevant conflicts of interest to declare." @default.
• W137671273 created "2016-06-24" @default.
• W137671273 creator A5022367860 @default.
• W137671273 creator A5025468259 @default.
• W137671273 creator A5027080346 @default.
• W137671273 creator A5032317350 @default.
• W137671273 creator A5066709583 @default.
• W137671273 creator A5069673223 @default.
• W137671273 creator A5072356249 @default.
• W137671273 creator A5089854184 @default.
• W137671273 date "2013-11-15" @default.
• W137671273 modified "2023-09-28" @default.
• W137671273 title "Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model" @default.
• W137671273 doi "https://doi.org/10.1182/blood.v122.21.645.645" @default.
• W137671273 hasPublicationYear "2013" @default.
• W137671273 type Work @default.
• W137671273 sameAs 137671273 @default.
• W137671273 citedByCount "2" @default.
• W137671273 countsByYear W1376712732014 @default.
• W137671273 crossrefType "journal-article" @default.
• W137671273 hasAuthorship W137671273A5022367860 @default.
• W137671273 hasAuthorship W137671273A5025468259 @default.
• W137671273 hasAuthorship W137671273A5027080346 @default.
• W137671273 hasAuthorship W137671273A5032317350 @default.
• W137671273 hasAuthorship W137671273A5066709583 @default.
• W137671273 hasAuthorship W137671273A5069673223 @default.
• W137671273 hasAuthorship W137671273A5072356249 @default.
• W137671273 hasAuthorship W137671273A5089854184 @default.
• W137671273 hasConcept C113067387 @default.
• W137671273 hasConcept C157695867 @default.
• W137671273 hasConcept C159654299 @default.
• W137671273 hasConcept C190283241 @default.
• W137671273 hasConcept C203014093 @default.
• W137671273 hasConcept C2777525834 @default.
• W137671273 hasConcept C2777938653 @default.
• W137671273 hasConcept C2778453870 @default.
• W137671273 hasConcept C2778461978 @default.
• W137671273 hasConcept C2778957590 @default.
• W137671273 hasConcept C2779338263 @default.
• W137671273 hasConcept C2779878957 @default.
• W137671273 hasConcept C29537977 @default.
• W137671273 hasConcept C42362537 @default.
• W137671273 hasConcept C502942594 @default.
• W137671273 hasConcept C54355233 @default.
• W137671273 hasConcept C553184892 @default.
• W137671273 hasConcept C55493867 @default.
• W137671273 hasConcept C62478195 @default.
• W137671273 hasConcept C81885089 @default.
• W137671273 hasConcept C86803240 @default.
• W137671273 hasConcept C90059517 @default.
• W137671273 hasConcept C95444343 @default.
• W137671273 hasConcept C98274493 @default.
• W137671273 hasConceptScore W137671273C113067387 @default.
• W137671273 hasConceptScore W137671273C157695867 @default.
• W137671273 hasConceptScore W137671273C159654299 @default.
• W137671273 hasConceptScore W137671273C190283241 @default.
• W137671273 hasConceptScore W137671273C203014093 @default.
• W137671273 hasConceptScore W137671273C2777525834 @default.
• W137671273 hasConceptScore W137671273C2777938653 @default.
• W137671273 hasConceptScore W137671273C2778453870 @default.
• W137671273 hasConceptScore W137671273C2778461978 @default.
• W137671273 hasConceptScore W137671273C2778957590 @default.
• W137671273 hasConceptScore W137671273C2779338263 @default.
• W137671273 hasConceptScore W137671273C2779878957 @default.
• W137671273 hasConceptScore W137671273C29537977 @default.
• W137671273 hasConceptScore W137671273C42362537 @default.
• W137671273 hasConceptScore W137671273C502942594 @default.
• W137671273 hasConceptScore W137671273C54355233 @default.
• W137671273 hasConceptScore W137671273C553184892 @default.
• W137671273 hasConceptScore W137671273C55493867 @default.
• W137671273 hasConceptScore W137671273C62478195 @default.
• W137671273 hasConceptScore W137671273C81885089 @default.
• W137671273 hasConceptScore W137671273C86803240 @default.
• W137671273 hasConceptScore W137671273C90059517 @default.
• W137671273 hasConceptScore W137671273C95444343 @default.
• W137671273 hasConceptScore W137671273C98274493 @default.
• W137671273 hasLocation W1376712731 @default.
• W137671273 hasOpenAccess W137671273 @default.
• W137671273 hasPrimaryLocation W1376712731 @default.
• W137671273 hasRelatedWork W1857171412 @default.
• W137671273 hasRelatedWork W194958640 @default.
• W137671273 hasRelatedWork W2100293658 @default.
• W137671273 hasRelatedWork W2118863989 @default.
• W137671273 hasRelatedWork W2270238912 @default.
• W137671273 hasRelatedWork W2463716169 @default.
• W137671273 hasRelatedWork W2553952472 @default.
• W137671273 hasRelatedWork W2554863425 @default.
• W137671273 hasRelatedWork W2566505248 @default.
• W137671273 hasRelatedWork W2568089859 @default.
• W137671273 hasRelatedWork W2585746906 @default.
• W137671273 hasRelatedWork W2593195632 @default.
• W137671273 hasRelatedWork W2593792877 @default.
• W137671273 hasRelatedWork W2739544745 @default.
• W137671273 hasRelatedWork W2902413705 @default.
• W137671273 hasRelatedWork W2977107998 @default.
• W137671273 hasRelatedWork W2977690683 @default.
• W137671273 hasRelatedWork W2979896473 @default.
• W137671273 hasRelatedWork W3150877074 @default.
• W137671273 hasRelatedWork W3180907850 @default.
• W137671273 isParatext "false" @default.

• next